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Ontologies set the rules for describing such things and are 
therefore often explained as formal frameworks for 
representing knowledge. Many (200+) biomedical ontologies 
exist and a comprehensive repository can be found at the 
Bioportal (http://bioportal.bioontology.org/). The Radiation 
Oncology Ontology can be found at the Bioportal and a new 
ontology that tries to describe the radiation oncology 
domain.  
Part of an ontology’s formal definition is the assignment of a 
code or identifier to each entity. With the advent of 
Semantic Web technology and specifically the Web Ontology 
Language (OWL) these identifiers take the form of the web 
standard Uniform Resource Identifiers. As an example in the 
NCI Thesaurus, Intensity-Modulated Radiation Therapy has 
the URI  
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1613
5.   
When people use the same ontology and thus the same URI to 
code things, the datasets they generate are much more 
interoperable and can thus more easily be shared compared 
to using one’s own terms and definitions to describe things. 
An ultimate goal of these efforts is to re-use clinical and 
research data in such a way that all radiation oncology 
becomes Linked Data, “a method of publishing structured 
data so that it can be interlinked and become more useful”.  
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“Omics” approaches, particularly genomics, have been part 
of the drive towards the need for “big-data” to allow for 
meaningful analyses of the effects of complex factors and 
their interactions. To achieve such data in a timely manner 
has led to the establishment of an ever increasing number of 
scientific consortia that allow for the rapid pooling of both 
biological samples and their associated meta-data. Such 
consortia normally involve multiple individual smaller studies 
across several countries and often continents. This in turn 
raises challenges for the approach to biobanking and for the 
equitable sharing of the combined resource. 
Two broad approaches to the biobanking have been adopted: 
1.      The individual study samples are sent and centrally 
pooled and analysed.  
2.      The samples are retained and analysed locally by the 
individual studies and the subsequent electronic data pooled. 
The first approach has the advantage of a more uniform 
approach to the analysis of the ensuing sample biobank but 
raises issues around appropriate documented material 
transfer arrangements. Such documentation is often not 
trivial and can run into difficulties in terms of the individual 
studies own legal and ethical restrictions on their wider use. 
It can also raise potential challenges to the storage and 
organisation of the samples to allow for subsequent efficient 
use in addition to issues around open and fair collaborative 
models of working that should allow for each contributing 
partner to have equitable access to the pooled resource. 
The second approach raises a different set of issues in terms 
of ensuring quality and consistency of analyses of the samples 
themselves across multiple labs and potentially different 
platforms. Furthermore, whilst allowing the individual studies 
seemingly greater retained “ownership” of the samples 
themselves the transfer of the ensuing data still raises the 
need for appropriate protocols for the ensuing controlled use 
of the pooled dataset itself. 
Both approaches thus have their inherent limitations and 
both models continue to be used across different consortia. 
We will demonstrate some of the issues raised in practice 
using examples from our experience of involvement in large 
scale consortia in cancer. Particular issues around the time 
taken to achieve the appropriate paperwork for pooling raise 
important considerations for the planning of further 
initiatives whilst issues around equitable access give rise to 
potential feelings of unfairness and reduced willingness to 
participate in further consortia initiatives. Appropriate 
biobanking practices necessary for any subsequent re-
sampling will also be considered. Such real and potentially 
imagined factors raise important issues going forwards with 
the “big data” agenda and could limit the most rapid and 
powerful integration of studies in the future.  
In conclusion important lessons learnt from early consortia 
building initiatives, which have largely been built based on 
common sense principles, need to be learnt and integrated 
with more rigorous formal management standards such as ISO 
9001, to maximise the utility and efficiency of large scale 
biobanks  going forwards. 
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Imaging data are increasingly used in radiotherapy. 
Functional imaging with FDG-PET is currently tested in 
several trials of dose painting. The versatility of MRI affords 
both anatomical and functional images: T2-weighted MRI 
provides anatomical detail with excellent soft-tissue 
contrast; diffusion-weighted MRI has potential as an early 
marker for response to treatment; dynamic contrast-
enhanced MRI reflects the properties of the microvasculature 
in tissue. A clear connection with hypoxia has been 
established in cervical cancer and its prognostic value is also 
suggested in head and neck cancer. Increasingly, these 
imaging techniques are therefore added to clinical trial 
protocols to guide decisions about target delineation and 
dose levels, but also to monitor treatment response. 
Traditionally, a qualitative interpretation of the data is given 
by the nuclear medicine physician or radiologist. This is 
sensitive to variations in imaging protocols influencing the 
appearance of the images. It also is subjective and relies 
strongly on observer experience. The use of quantitative, 
rather than qualitative data can be a solution to this 
problem. For PET, the Standard Uptake Value (SUV) has 
become the prevailing method to represent the data. Similar 
opportunities exist for MRI. T2-mapping combines anatomical 
information with quantitative information about the T2-value 
of the tissue. For diffusion-weighted imaging, the apparent 
diffusion coefficient (ADC) is a reproducible metric. For 
dynamic contrast-enhanced MRI, tracer kinetic modeling is 
used to extract quantitative data.  
Quantification thus holds the prospect to provide data that 
are consistent between institutes and types of scanners. 
However, the advancement in understanding the value of 
imaging methods is held back by a lack of consistency in 
methodology. Different methods for acquisition and analysis 
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make comparison of results between different studies 
difficult and standardization is called for.  The quantitative 
imaging biomarker alliance (QIBA) is an example of an 
initiative that aims to improve the value and practicality of 
quantitative imaging biomarkers by reducing variability 
across devices, patients and time. 
Whereas standardization in methodology is important for 
quantification, it has to be able to accommodate emerging 
new techniques. It is untenable to continue using outdated 
methods, simply because earlier studies did not have access 
to more advanced equipment. Therefore, within a 
multicenter project using quantitative MRI for imaging cancer 
in the prostate and cervix, we developed a procedure that 
allows each center to use the optimal sequences for their 
scanner. In a series of phantom and volunteer experiments 
these sequences are benchmarked against well-established 
sequences which are robust, but typically too slow for clinical 
use. Consistent quantification with a bias of a few percent 
between different scanners and institutes was feasible for T2 
mapping, as well as for diffusion-weighted MRI. With newer 
scanners and sequences typically more precise results were 
obtained. This strategy is therefore a way to achieve 
consistency between quantitative results from different 
centers and studies.  
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Clinical trials are considered as the most rigorous way to 
prospectively evaluate the efficacy and toxicity of 
treatments. When randomized designs are used they also 
provide comparative effectiveness between several 
therapies. Good Clinical Practice is the universal ethical and 
scientific quality standard for conducting clinical trials and 
applies to all aspects of the clinical trial process. Quality is 
viewed as a continuum, going from trial design to analysis 
and reporting. The quality of a clinical trial at an investigator 
site is usually assessed by sponsor audits and regulatory 
inspections, but radiation oncology trials can, through RTQA 
procedures, include an innovative means of quality 
assessment which can ultimately generate data and 
hypotheses. The Clinical Trials Transformation Initiative has 
defined quality as “the ability to effectively answer the 
intended question about the benefits and risks of a medical 
product (therapeutic or diagnostic) or procedure, while 
assuring protection of human subjects”. 
The different issues of quality in clinical trials will be 
discussed, including trial design, statistical hypotheses, 
interventions, data recording and monitoring, statistical 
analysis, trial reporting and interpretation. Means to improve 
trials quality and generalization of trials’ results will also be 
discussed. All the limitations to data quality in prospective 
trials described will also apply to other forms of clinical 
research, such as data-mining, and are usually minimized and 
controlled in randomized trials. It is crucial to allow external 
audit and meta-analyses, as these procedures can identify 
and potentially reduce biases. Ultimately the reader is the 
last judge of trial quality through the critical reading of 
medical literature.  
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Aim: ESTRO has formed a task force on risk management 
within radiation oncology (RO).  ESTRO represents all the 
professionals working within RO and is therefore the most 
appropriate partner to work with on issues relating to risk 
and risk management within radiotherapy.  One example is in 
the implementation of the latest EU directive on basic safety 
standard in radiation protection, which will make reporting 
and learning from incidents and near incidents a legal 
requirement.  ESTRO works closely with the National 
Societies in EU and is ideally positioned to inform and advise 
on this and all other related issues. 
Methods: The remit of the working group was to define the 
specific tasks that should be carried out.  These include: 
•       To develop a body of knowledge in order to position 
ESTRO such that they can inform and influence policy with 
respect to risk management in radiotherapy at the level, for 
instance of the European Commission 
•       To prepare and disseminate information to the National 
Societies and the ESTRO community on important 
developments in the area of risk management and incident 
reporting and learning that they should be aware of.   
•       To position ESTRO as an interface with other 
professional bodies such as ASTRO/AAPM to ensure 
consistency of approach internationally.   
•       To liaise between European and global bodies, the 
National Societies and the ESTRO community to advise with 
respect to effective implementation of the new EURATOM 
Directive. 
•       To carry out a scoping exercise of all the current 
activities in the area of risk management and incident 
learning specifically to identify variations and 
inconsistencies. 
 Incident Learning Systems (ILS): 
 •       ROSIS, SAFRON (IAEA) 
 •       RO-ILS (ASTRO/AAPM) 
 •       National Reporting and Learning System – 
NRLS with specific coding for RT (UK) 
 •       Canadian Partneship for Quality in 
Radiotherapy – CPQR (Ca) 
 •       Etc… 
 
Consistent with the requirements of the new EURATOM Basic 
Safety Standards which will mandate new measures in 
relation to risk management in radiotherapy, the ESTRO, as 
the European professional body in radiotherapy should be in a 
position to give direction in relation to (for example): 
What should be considered a mandatory reportable event 
Carrying out prospective analysis when new technology is 
introduced 
